Sarah Gray

4.7k total citations · 6 hit papers
24 papers, 3.6k citations indexed

About

Sarah Gray is a scholar working on Ophthalmology, Hematology and Genetics. According to data from OpenAlex, Sarah Gray has authored 24 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Ophthalmology, 7 papers in Hematology and 6 papers in Genetics. Recurrent topics in Sarah Gray's work include Retinal Diseases and Treatments (7 papers), Iron Metabolism and Disorders (6 papers) and Hemoglobinopathies and Related Disorders (6 papers). Sarah Gray is often cited by papers focused on Retinal Diseases and Treatments (7 papers), Iron Metabolism and Disorders (6 papers) and Hemoglobinopathies and Related Disorders (6 papers). Sarah Gray collaborates with scholars based in United States, United Kingdom and Egypt. Sarah Gray's co-authors include Namrata Saroj, Wendy Yee Murahashi, Roman G. Rubio, Peter A. Campochiaro, Amy Chen Rundle, David M. Brown, Zhengrong Li, Rishi P. Singh, Jeffrey S. Heier and Leonard Feiner and has published in prestigious journals such as Blood, PLoS ONE and Journal of Allergy and Clinical Immunology.

In The Last Decade

Sarah Gray

23 papers receiving 3.5k citations

Hit Papers

Ranibizumab for Macular Edema following Central Retinal V... 2010 2026 2015 2020 2010 2010 2011 2011 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
    2010 926 citations David M. Brown, Peter A. Campochiaro et al. Ophthalmology profile →
  2. Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion
    2010 634 citations Peter A. Campochiaro, Jeffrey S. Heier et al. Ophthalmology profile →
  3. Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study
    2011 575 citations Peter A. Campochiaro, David M. Brown et al. Ophthalmology profile →
  4. Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study
    2011 376 citations David M. Brown, Peter A. Campochiaro et al. Ophthalmology profile →
  5. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
    2016 350 citations Nicola A. Hanania, Phillip E. Korenblat et al. The Lancet Respiratory Medicine profile →
  6. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration
    2018 264 citations Frank G. Holz, Srinivas R. Sadda et al. JAMA Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Gray United States 12 2.8k 1.7k 592 409 358 24 3.6k
Dustan Kangave Saudi Arabia 31 1.7k 0.6× 571 0.3× 80 0.1× 262 0.6× 139 0.4× 49 2.1k
Anne Marie Lane United States 26 1.2k 0.4× 469 0.3× 64 0.1× 420 1.0× 151 0.4× 57 2.0k
Robert Vitti United States 27 4.8k 1.7× 3.7k 2.1× 76 0.1× 697 1.7× 156 0.4× 60 5.1k
John R. Gonder Canada 25 1.3k 0.5× 614 0.4× 45 0.1× 594 1.5× 91 0.3× 64 1.9k
Ezekiel Weis Canada 22 909 0.3× 317 0.2× 36 0.1× 220 0.5× 74 0.2× 72 1.5k
Anton Haas Austria 21 1.8k 0.6× 1.2k 0.7× 46 0.1× 272 0.7× 69 0.2× 90 2.2k
Roman G. Rubio United States 25 6.6k 2.4× 4.8k 2.8× 64 0.1× 731 1.8× 162 0.5× 58 7.1k
Jennifer Visich United States 19 302 0.1× 458 0.3× 43 0.1× 208 0.5× 277 0.8× 34 1.1k
A Pätz United States 18 1.1k 0.4× 800 0.5× 41 0.1× 354 0.9× 23 0.1× 61 1.6k
Jing Shi China 16 108 0.0× 502 0.3× 56 0.1× 250 0.6× 306 0.9× 46 1.6k

Countries citing papers authored by Sarah Gray

Since Specialization
Citations

This map shows the geographic impact of Sarah Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Gray more than expected).

Fields of papers citing papers by Sarah Gray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Gray. The network helps show where Sarah Gray may publish in the future.

Co-authorship network of co-authors of Sarah Gray

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Gray. A scholar is included among the top collaborators of Sarah Gray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Gray. Sarah Gray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mansour, Diana, et al.. (2024). The evolving perspective of menopause management in the United Kingdom. Women s Health. 20. 912699329–912699329. 3 indexed citations
3.
Achebe, Maureen, Hoda Hassab, Salam Alkindi, et al.. (2023). Over 4 Years of Safety and Efficacy with Voxelotor Treatment for Patients with Sickle Cell Disease: Updated Results from an Open-Label Extension of the Phase 3 HOPE Trial. Blood. 142(Supplement 1). 2527–2527. 4 indexed citations
4.
Rozenberg, Serge, et al.. (2023). Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts’ perspective. Expert Review of Clinical Pharmacology. 16(6). 507–517. 6 indexed citations
5.
Howard, Jo, Kenneth I. Ataga, Robert C. Brown, et al.. (2021). Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Haematology. 8(5). e323–e333. 61 indexed citations
6.
Vichinsky, Elliott, Victor R. Gordeuk, Paul Telfer, et al.. (2020). Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study. Blood. 136(Supplement 1). 31–32. 13 indexed citations
7.
Heier, Jeffrey S., Dante J. Pieramici, Usha Chakravarthy, et al.. (2020). Visual Function Decline Resulting from Geographic Atrophy. Ophthalmology Retina. 4(7). 673–688. 73 indexed citations
8.
Pieramici, Dante J., Frank G. Holz, Jeffrey S. Heier, et al.. (2018). Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs). Investigative Ophthalmology & Visual Science. 59(9). 4948–4948. 2 indexed citations
9.
Gray, Sarah & Bertil Axelsson. (2018). The prevalence of deranged C-reactive protein and albumin in patients with incurable cancer approaching death. PLoS ONE. 13(3). e0193693–e0193693. 24 indexed citations
10.
Holz, Frank G., Srinivas R. Sadda, Brandon Busbee, et al.. (2018). Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration. JAMA Ophthalmology. 136(6). 666–666. 264 indexed citations breakdown →
11.
Fortinsky, Kyle J., Myriam Martel, Samir C. Grover, et al.. (2016). Red Blood Cell Transfusions and Iron Therapy for Patients Presenting with Acute Upper Gastrointestinal Bleeding: A Survey of Canadian Gastroenterologists and Hepatologists. Canadian Journal of Gastroenterology and Hepatology. 2016. 1–8. 3 indexed citations
12.
Hanania, Nicola A., Phillip E. Korenblat, Kenneth R. Chapman, et al.. (2016). Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. The Lancet Respiratory Medicine. 4(10). 781–796. 350 indexed citations breakdown →
13.
Corren, Jonathan, Nicola A. Hanania, Phillip E. Korenblat, et al.. (2016). Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma. Journal of Allergy and Clinical Immunology. 137(2). AB13–AB13. 2 indexed citations
14.
Hanania, Nicola A., Phillip E. Korenblat, Kenneth R. Chapman, et al.. (2016). LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma. OA1975–OA1975. 1 indexed citations
15.
Hanania, Nicola A., Michael Noonan, Jonathan Corren, et al.. (2015). Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 70(8). 748–756. 299 indexed citations
16.
Brown, David M., Peter A. Campochiaro, Robert B. Bhisitkul, et al.. (2011). Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study. Ophthalmology. 118(8). 1594–1602. 376 indexed citations breakdown →
17.
Campochiaro, Peter A., David M. Brown, Carl C. Awh, et al.. (2011). Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study. Ophthalmology. 118(10). 2041–2049. 575 indexed citations breakdown →
18.
Ho, Allen C., et al.. (2010). Ranibizumab in Patients With Macular Edema Following Retinal Vein Occlusion: 12-Month Outcomes of BRAVO and CRUISE. Investigative Ophthalmology & Visual Science. 51(13). 6452–6452. 2 indexed citations
19.
Campochiaro, Peter A., Jeffrey S. Heier, Leonard Feiner, et al.. (2010). Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion. Ophthalmology. 117(6). 1102–1112.e1. 634 indexed citations breakdown →
20.
Brown, David M., Peter A. Campochiaro, Rishi P. Singh, et al.. (2010). Ranibizumab for Macular Edema following Central Retinal Vein Occlusion. Ophthalmology. 117(6). 1124–1133.e1. 926 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dustan Kangave Breakdown of academic impact, for papers by Anne Marie Lane Breakdown of academic impact, for papers by Robert Vitti Breakdown of academic impact, for papers by John R. Gonder Breakdown of academic impact, for papers by Ezekiel Weis Breakdown of academic impact, for papers by Anton Haas Breakdown of academic impact, for papers by Roman G. Rubio Breakdown of academic impact, for papers by Jennifer Visich Breakdown of academic impact, for papers by A Pätz Breakdown of academic impact, for papers by Jing Shi
Rankless by CCL
2026